<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04380597</url>
  </required_header>
  <id_info>
    <org_study_id>ENUPS</org_study_id>
    <nct_id>NCT04380597</nct_id>
  </id_info>
  <brief_title>Observational Study in Patients With Nail Psoriasis Treated With Enstilar® to Assess the Severity Change and the Quality of Life</brief_title>
  <acronym>ENUPS</acronym>
  <official_title>Observational and Prospective Study in Patients With Nail Psoriasis Treated With Calcipotriene and Betamethasone Dipropionate Aerosol Foam to Evaluate the Change in the Severity of Psoriasis and in the Quality of Life</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Angeles Florez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Complejo Hospitalario Universitario de Pontevedra</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observational, prospective and multicentre study to evaluate the effectiveness of
      calcipotriene and betamethasone dipropionate aerosol foam (Cal / BD), prescribed according to
      clinical practice and following the Product Data Sheet instructions, in the topical treatment
      of nail psoriasis according to the change in the score of the Nail Psoriasis Severity Index
      (NAPSI) at 12 weeks of treatment with respect to the initial score.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 26, 2019</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Actual">December 15, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Nail Psoriasis Severity Index (NAPSI)</measure>
    <time_frame>Baseline</time_frame>
    <description>Numeric, reproducible, objective, simple tool for evaluation of nail psoriasis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nail Psoriasis Severity Index (NAPSI)</measure>
    <time_frame>Week 12 of treatment</time_frame>
    <description>Numeric, reproducible, objective, simple tool for evaluation of nail psoriasis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nail Psoriasis Severity Index (NAPSI)</measure>
    <time_frame>Week 24 of treatment</time_frame>
    <description>Numeric, reproducible, objective, simple tool for evaluation of nail psoriasis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA)</measure>
    <time_frame>Baseline, Week 12 of treatment and Week 24 of treatment</time_frame>
    <description>Modular instrument for the assessment of clinical and patient-reported outcomes in nails.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Hands Photographs</measure>
    <time_frame>Baseline, Week 12 of treatment and Week 24 of treatment</time_frame>
    <description>High-quality photographs on patient´s both hands to document the psoriasis status</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Nail Psoriasis</condition>
  <arm_group>
    <arm_group_label>Patients with nail psoriasis</arm_group_label>
    <description>Patients with nail psoriasis who are prescribed, according to clinical practice, a topical treatment with calcipotriene and betamethasone dipropionate aerosol foam.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcipotriene and betamethasone dipropionate aerosol foam</intervention_name>
    <description>Prescribed according to clinical practice and following Product Data Sheet instructions</description>
    <arm_group_label>Patients with nail psoriasis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed of nail psoriasis for whom are prescribed, according to clinical
        practice, a topical treatment. Will be included the first 60 patients that consecutively
        attend the participating centers and meet all the eligibility criteria.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with nail psoriasis who start, according to clinical practice, topical
             treatment with calcipotriene and betamethasone dipropionate aerosol foam

          -  Patients who authorize their participation in the study by signing written informed
             consent.

        Exclusion Criteria:

          -  Patients receiving treatment with systemic drugs or their prescription is scheduled
             for the next 3 months. However, may be included patients who receive the same systemic
             treatment regimen from at least 6 months before their inclusion in the study and up to
             14 weeks later.

          -  Patients with any situation or state that in the opinion of the investigator
             discourages their participation in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Pontevedra</name>
      <address>
        <city>Pontevedra</city>
        <zip>36001</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 7, 2019</study_first_submitted>
  <study_first_submitted_qc>May 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2020</study_first_posted>
  <last_update_submitted>May 7, 2020</last_update_submitted>
  <last_update_submitted_qc>May 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Complejo Hospitalario Universitario de Pontevedra</investigator_affiliation>
    <investigator_full_name>Angeles Florez</investigator_full_name>
    <investigator_title>Head of Dermatology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Betamethasone Valerate</mesh_term>
    <mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
    <mesh_term>Betamethasone benzoate</mesh_term>
    <mesh_term>Calcipotriene</mesh_term>
    <mesh_term>Betamethasone sodium phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

